We tested whether the deletion of Nocturnin rescues neurodegeneration in vivo in a double transgenic PD mouse model overexpressing human mutant alpha-synuclein A53T selectively in dopaminergic neurons (DASYN53). The gene discussed is NOCT; the disease is Parkinson disease.